Maria-Athina Altzerinakou1, Xavier Paoletti2. 9 May, 2017
|
|
- Arleen Carpenter
- 5 years ago
- Views:
Transcription
1 An adaptive design for the identification of the optimal dose using joint modelling of efficacy and toxicity in phase I/II clinical trials of molecularly targeted agents Maria-Athina Altzerinakou1, Xavier Paoletti2 1. CESP OncoStat, INSERM, Université Paris-Saclay, Université Paris-Sud, UVSQ, Institut Gustave Roussy, Villejuif, France 2. Institut Gustave Roussy, CESP OncoStat, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France 9 May, 2017
2 Contents 1 General framework Maria-Athina Altzerinakou Inserm 2 / 18
3 Current challenges I Maria-Athina Altzerinakou Inserm 3 / 18
4 Current challenges I Probability of efficacy Dose Association of efficacy and dose in cytotoxic and cytostatic agents, respectively. Maria-Athina Altzerinakou Inserm 3 / 18
5 Current challenges II Evaluation of the MTD, using data collected during the first treatment cycle. 1 Ignore late onset toxicities 2 Ignore cumulative toxicities after extensive exposure to a specific dose level 3 Ignore information on efficacy measurements 1,2 1. Postel-Vinay, S. et al. (2011). Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities? J Clin Oncol, 29(13): Soria, J-C. (2011). Phase 1 trials of molecular targeted therapies: Are we evaluating toxicities properly? European Journal of Cancer, 47(10): Maria-Athina Altzerinakou Inserm 4 / 18
6 Objective Propose an adaptive design for phase I/II trials Define a maximum tolerated dose (MTD) and an optimal dose (OD) MTD: The maximal dose acceptably tolerated cumulatively over all treatment cycles OD: A dose that maximizes the efficacy, while satisfying certain toxicity requirements Combine data of time to first severe toxicity and biomarker efficacy over several treatment cycles Maria-Athina Altzerinakou Inserm 5 / 18
7 Population Evaluation of toxicity End of treatment cycle Evaluation of efficacy Fixed time within cycles Drop out: 1) Dose limiting toxicity 2) Lack of efficacy 3) Non-informative censoring Maria-Athina Altzerinakou Inserm 6 / 18
8 Joint modelling Joint modelling of interval censored time to first severe toxicity data repeated efficacy measurements on a continuous scale shared random effects Why joint modelling??? Incorporate information on efficacy utilize all available information Take into account missing Maria-Athina Altzerinakou Inserm 7 / 18
9 Model selection t time of visit d dose c treatment cycle Linear mixed effects model - Efficacy Y j = β 0 + β 1 t 2 j + β 2 t j d + β 3 t j log d + ut j + Z j, j (0, 3m) and t j < m where Y measured on continuous scale, u N(0, σ 2 ) random effects and Z MVN(0, v 2 I) mutually independent measurement errors. Maria-Athina Altzerinakou Inserm 8 / 18
10 Model selection t time of visit d dose c treatment cycle Linear mixed effects model - Efficacy Y j = β 0 + β 1 t 2 j + β 2 t j d + β 3 t j log d + ut j + Z j, j (0, 3m) and t j < m where Y measured on continuous scale, u N(0, σ 2 ) random effects and Z MVN(0, v 2 I) mutually independent measurement errors. Probit model - Toxicity P(S = s S > s 1, U) = 1 Φ {δ 0 + δ 1 c + δ c d + γu}, s = 1, 2,..., m + 1 where Φ standard N, δ c is a constant and u is the shared random time slope. Key assumption: Given the random effect the two processes are independent Maria-Athina Altzerinakou Inserm 8 / 18
11 Why this joint modelling method? Exact likelihood inference (skew normal distribution properties) 3,4 avoid numerical integration of approximate likelihood Better parameter estimations Small bias, even with small sample sizes Satisfying coverage More rapid estimations Suggested after 25 subjects 3. Barrett, J. et al. (2015). Joint modelling of repeated measurements and time-to-event outcomes: flexible model specification and exact likelihood inference. J R Stat Soc Series B Stat Methodol., 77(1): Arnold, B.C. (2009). Flexible univariate and multivariate models based on hidden truncation. J. Statist. Planng Inf., 139(11): Maria-Athina Altzerinakou Inserm 9 / 18
12 Design Steps Probit survival model Time to first severe toxicity Intervals - treatment cycles 2+2 Probit-CRM Joint Modelling Dose allocation Cohorts of 1 patient Estimation of model parameters Estimation of toxicity over several treatment cycles Dose allocation Maria-Athina Altzerinakou Inserm 10 / 18
13 Scenario Objective: Evaluate the correct selection of the MTD and OD, through different sets of scenarios and extensive simulations. 60 patients 6 dose levels 6 treatment cycles max 18 visits per patient (balanced data, 3 per cycle) drop outs based on DLTs, lack of efficacy or non-informative censoring target toxicity level 40% after 6 cycles max mean clinical difference between 2 doses 20 units Maria-Athina Altzerinakou Inserm 11 / 18
14 Simulation results Table 1: Selection percentage of each dose at the end of the trial, on 1080 simulations Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 1 (Eff, Tox) (43, 0.03%) (52, 0.35%) (62, 2.40%) (71, 11.2%) (80, 34.3%) (89, 68.2%) n/ % (Eff, Tox) (24, 34.9%) (39, 67%) (55, 90.7%) (70, 98.7%) (85, 99.9%) (100, 99.9%) n/ % (Eff, Tox) (24, 0.03%) (39, 0.03%) (55, 2.40%) (70, 11.2%) (85, 34.3%) (100, 68.2%) n/ % (Eff, Tox) (39, 1.9%) (42, 7.30%) (45, 20.4%) (48, 42.5%) (52, 68.1%) (55, 87.8%) n/ % (Eff, Tox) (24, 0.01%) (56, 0.11%) (88, 0.71%) (120, 3.49%) (152, 12.6%) (183, 33.1%) n/ % (Eff, Tox) (24, 0.01%) (39, 0.11%) (55, 0.71%) (70, 3.49%) (85, 12.6%) (100, 33.1%) n/ % Maria-Athina Altzerinakou Inserm 12 / 18
15 Conclusions Identification of the OD > 98% correct dose selection when OD is on the tail of the dose range > 71% correct dose selection when OD is in the middle of the dose range 0% OD selection above the MTD Maria-Athina Altzerinakou Inserm 13 / 18
16 Discussion High percentage of correct OD selection Dose selection within a safe yet efficient range of doses Exclusion of patients due to lack of efficacy Model cannot identify accurately beginning of the plateau Maria-Athina Altzerinakou Inserm 14 / 18
17 Thank you! This project has received funding from the European Union s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No Maria-Athina Altzerinakou Inserm 15 / 18
18 Efficacy in time Time Efficacy over time per dose Efficacy dose 1 dose 2 dose 3 dose 4 dose 5 dose Time Maria-Athina Altzerinakou Inserm 16 / 18
19 Bias Table 1: Bias of parameter estimations of time to event and longitudinal joint model, within 5000 simulations per sample size Sample Size Parameters n=15 n=20 n=30 n=60 n=100 Longitudinal Intercept Longitudinal Time Longitudinal Dose Survival Intercept Survival Time Survival Dose Longitudinal Residual Variance Longitudinal Slope Variance Survival Gamma Maria-Athina Altzerinakou Inserm 17 / 18
20 Coverage Table 2: Coverage of parameter estimations of time to event and longitudinal joint model, within 5000 simulations per sample size Sample Size Parameters n=15 n=20 n=30 n=60 n=100 Longitudinal Intercept Longitudinal Time Longitudinal Dose Survival Intercept Survival Time Survival Dose Longitudinal Residual Variance Longitudinal Slope Variance Survival Gamma Maria-Athina Altzerinakou Inserm 18 / 18
Optimal dose selection considering both toxicity and activity data; plateau detection for molecularly targeted agents
Optimal dose selection considering both toxicity and activity data; plateau detection for molecularly targeted agents Maria-Athina Altzerinakou1,2,3 and Xavier Paoletti3,1,2 1. CESP OncoStat, Inserm, Villejuif,
More informationA novel approach to estimation of the time to biomarker threshold: Applications to HIV
A novel approach to estimation of the time to biomarker threshold: Applications to HIV Pharmaceutical Statistics, Volume 15, Issue 6, Pages 541-549, November/December 2016 PSI Journal Club 22 March 2017
More informationModelling prognostic capabilities of tumor size: application to colorectal cancer
Session 3: Epidemiology and public health Modelling prognostic capabilities of tumor size: application to colorectal cancer Virginie Rondeau, INSERM Modelling prognostic capabilities of tumor size : application
More informationJoint modeling and dynamic predictions with applications to cancer research
Joint modeling and dynamic predictions with applications to cancer research Agnieszka Król Postdoctoral Research Fellow Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto 17 novembre
More informationStatistical Tolerance Regions: Theory, Applications and Computation
Statistical Tolerance Regions: Theory, Applications and Computation K. KRISHNAMOORTHY University of Louisiana at Lafayette THOMAS MATHEW University of Maryland Baltimore County Contents List of Tables
More informationNew Challenges: Model-based Dose Finding in the Era of Targeted Agents
New Challenges: Model-based Dose Finding in the Era of Targeted Agents Elizabeth Garrett-Mayer, PhD 1 Cody Chiuzan, PhD 2 1 Hollings Cancer Center Department of Public Health Sciences Medical University
More informationAccommodating informative dropout and death: a joint modelling approach for longitudinal and semicompeting risks data
Appl. Statist. (2018) 67, Part 1, pp. 145 163 Accommodating informative dropout and death: a joint modelling approach for longitudinal and semicompeting risks data Qiuju Li and Li Su Medical Research Council
More informationPKPD modelling to optimize dose-escalation trials in Oncology
PKPD modelling to optimize dose-escalation trials in Oncology Marina Savelieva Design of Experiments in Healthcare, Issac Newton Institute for Mathematical Sciences Aug 19th, 2011 Outline Motivation Phase
More informationCorrecting AUC for Measurement Error
Correcting AUC for Measurement Error The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed Citable
More informationPrecision Medicine Lessons from meta-analyses of 70,253 patients
Precision Medicine Lessons from meta-analyses of 70,253 patients Razelle Kurzrock, MD Senior Deputy Director, Clinical Science Director, Center for Personalized Cancer Therapy and Clinical Trials Office
More informationCatherine A. Welch 1*, Séverine Sabia 1,2, Eric Brunner 1, Mika Kivimäki 1 and Martin J. Shipley 1
Welch et al. BMC Medical Research Methodology (2018) 18:89 https://doi.org/10.1186/s12874-018-0548-0 RESEARCH ARTICLE Open Access Does pattern mixture modelling reduce bias due to informative attrition
More informationScore Tests of Normality in Bivariate Probit Models
Score Tests of Normality in Bivariate Probit Models Anthony Murphy Nuffield College, Oxford OX1 1NF, UK Abstract: A relatively simple and convenient score test of normality in the bivariate probit model
More informationEffective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.
Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development Pantelis Vlachos Cytel Inc, Geneva Acknowledgement Joint work with Giacomo Mordenti, Grünenthal Virginie
More informationThe Changing Landscape of Phase I Trials in Cancer: A Novel Design for Dose Finding in the Era of Non-Cytotoxic Agents
The Changing Landscape of Phase I Trials in Cancer: A Novel Design for Dose Finding in the Era of Non-Cytotoxic Agents Elizabeth Garrett-Mayer, PhD 1 Cody Chiuzan, PhD 2 1 Hollings Cancer Center Department
More informationUtilizing the items from the MDS-UPDRS score to increase drug effect detection power in de novo idiopathic Parkinson's disease patients
Utilizing the items from the MDS-UPDRS score to increase drug effect detection power in de novo idiopathic Parkinson's disease patients Simon Buatois 1,3, Sylvie Retout 1, Nicolas Frey 1, Sebastian Ueckert
More informationQuality of meta-analyses and why they sometimes lead to different conclusions
Quality of meta-analyses and why they sometimes lead to different conclusions Jean-Pierre Pignon, MD, PhD Service de Biostatistique et d Epidémiologie, Ligue Nationale Contre le Cancer metaanalysis platform,
More informationChapter 1: Exploring Data
Chapter 1: Exploring Data Key Vocabulary:! individual! variable! frequency table! relative frequency table! distribution! pie chart! bar graph! two-way table! marginal distributions! conditional distributions!
More informationUsing dynamic prediction to inform the optimal intervention time for an abdominal aortic aneurysm screening programme
Using dynamic prediction to inform the optimal intervention time for an abdominal aortic aneurysm screening programme Michael Sweeting Cardiovascular Epidemiology Unit, University of Cambridge Friday 15th
More informationComprehensive evaluation of CRM, mtpi, and 3+3 relative to a benchmark
Comprehensive evaluation of CRM, mtpi, and 3+3 relative to a benchmark Bethany Jablonski Horton, Ph.D. University of Virginia April 16, 2015 Bethany Jablonski Horton, Ph.D. (UVA) Early Phase Dose Finding
More informationBayesian Dose Escalation Study Design with Consideration of Late Onset Toxicity. Li Liu, Glen Laird, Lei Gao Biostatistics Sanofi
Bayesian Dose Escalation Study Design with Consideration of Late Onset Toxicity Li Liu, Glen Laird, Lei Gao Biostatistics Sanofi 1 Outline Introduction Methods EWOC EWOC-PH Modifications to account for
More informationSpeaker: Clement Ma, PhD, Dana-Farber/Boston Children s Cancer and Blood Disorders Center, Harvard Medical School
October 24 2017 Speaker: Clement Ma, PhD, Dana-Farber/Boston Children s Cancer and Blood Disorders Center, Harvard Medical School Dr. Clement Ma is Lead Biostatistician at Dana-Farber/Boston Children s
More informationGenetic variation in FOXO3 is associated with reductions in inflammation and disease activity in inflammatory polyarthritis
Genetic variation in FOXO3 is associated with reductions in inflammation and disease activity in inflammatory polyarthritis Sebastien Viatte 1, James C. Lee 3,4, Bo Fu 1,5, Marion Espéli 6, Mark Lunt 7,
More informationDesign for Targeted Therapies: Statistical Considerations
Design for Targeted Therapies: Statistical Considerations J. Jack Lee, Ph.D. Department of Biostatistics University of Texas M. D. Anderson Cancer Center Outline Premise General Review of Statistical Designs
More informationAbstract. Introduction A SIMULATION STUDY OF ESTIMATORS FOR RATES OF CHANGES IN LONGITUDINAL STUDIES WITH ATTRITION
A SIMULATION STUDY OF ESTIMATORS FOR RATES OF CHANGES IN LONGITUDINAL STUDIES WITH ATTRITION Fong Wang, Genentech Inc. Mary Lange, Immunex Corp. Abstract Many longitudinal studies and clinical trials are
More informationA Comparison of Methods for Determining HIV Viral Set Point
STATISTICS IN MEDICINE Statist. Med. 2006; 00:1 6 [Version: 2002/09/18 v1.11] A Comparison of Methods for Determining HIV Viral Set Point Y. Mei 1, L. Wang 2, S. E. Holte 2 1 School of Industrial and Systems
More informationA web application for conducting the continual reassessment method
A web application for conducting the continual reassessment method Nolan A. Wages, PhD Biostatistics Shared Resource University of Virginia Cancer Center March 3, 2017 Dose-finding Setting Initial Safety
More informationRise of the Machines
Rise of the Machines Statistical machine learning for observational studies: confounding adjustment and subgroup identification Armand Chouzy, ETH (summer intern) Jason Wang, Celgene PSI conference 2018
More information2.75: 84% 2.5: 80% 2.25: 78% 2: 74% 1.75: 70% 1.5: 66% 1.25: 64% 1.0: 60% 0.5: 50% 0.25: 25% 0: 0%
Capstone Test (will consist of FOUR quizzes and the FINAL test grade will be an average of the four quizzes). Capstone #1: Review of Chapters 1-3 Capstone #2: Review of Chapter 4 Capstone #3: Review of
More informationMMI 409 Spring 2009 Final Examination Gordon Bleil. 1. Is there a difference in depression as a function of group and drug?
MMI 409 Spring 2009 Final Examination Gordon Bleil Table of Contents Research Scenario and General Assumptions Questions for Dataset (Questions are hyperlinked to detailed answers) 1. Is there a difference
More informationSimple Linear Regression the model, estimation and testing
Simple Linear Regression the model, estimation and testing Lecture No. 05 Example 1 A production manager has compared the dexterity test scores of five assembly-line employees with their hourly productivity.
More informationCase Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company
Case Studies in Bayesian Augmented Control Design Nathan Enas Ji Lin Eli Lilly and Company Outline Drivers for innovation in Phase II designs Case Study #1 Pancreatic cancer Study design Analysis Learning
More informationFlexible Matching in Case-Control Studies of Gene-Environment Interactions
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 59, No. Printed in U.S.A. DOI: 0.093/aje/kwg250 ORIGINAL CONTRIBUTIONS Flexible
More informationUsing mixture priors for robust inference: application in Bayesian dose escalation trials
Using mixture priors for robust inference: application in Bayesian dose escalation trials Astrid Jullion, Beat Neuenschwander, Daniel Lorand BAYES2014, London, 11 June 2014 Agenda Dose escalation in oncology
More informationBayesian Joint Modelling of Benefit and Risk in Drug Development
Bayesian Joint Modelling of Benefit and Risk in Drug Development EFSPI/PSDM Safety Statistics Meeting Leiden 2017 Disclosure is an employee and shareholder of GSK Data presented is based on human research
More informationWDHS Curriculum Map Probability and Statistics. What is Statistics and how does it relate to you?
WDHS Curriculum Map Probability and Statistics Time Interval/ Unit 1: Introduction to Statistics 1.1-1.3 2 weeks S-IC-1: Understand statistics as a process for making inferences about population parameters
More informationBayesian hierarchical modelling
Bayesian hierarchical modelling Matthew Schofield Department of Mathematics and Statistics, University of Otago Bayesian hierarchical modelling Slide 1 What is a statistical model? A statistical model:
More informationCentering Predictors
Centering Predictors Longitudinal Data Analysis Workshop Section 3 University of Georgia: Institute for Interdisciplinary Research in Education and Human Development Section 3: Centering Covered this Section
More informationAnalysis of left-censored multiplex immunoassay data: A unified approach
1 / 41 Analysis of left-censored multiplex immunoassay data: A unified approach Elizabeth G. Hill Medical University of South Carolina Elizabeth H. Slate Florida State University FSU Department of Statistics
More informationBusiness Statistics Probability
Business Statistics The following was provided by Dr. Suzanne Delaney, and is a comprehensive review of Business Statistics. The workshop instructor will provide relevant examples during the Skills Assessment
More informationAnalysis of Vaccine Effects on Post-Infection Endpoints Biostat 578A Lecture 3
Analysis of Vaccine Effects on Post-Infection Endpoints Biostat 578A Lecture 3 Analysis of Vaccine Effects on Post-Infection Endpoints p.1/40 Data Collected in Phase IIb/III Vaccine Trial Longitudinal
More informationSmall-area estimation of mental illness prevalence for schools
Small-area estimation of mental illness prevalence for schools Fan Li 1 Alan Zaslavsky 2 1 Department of Statistical Science Duke University 2 Department of Health Care Policy Harvard Medical School March
More informationHeritability. The Extended Liability-Threshold Model. Polygenic model for continuous trait. Polygenic model for continuous trait.
The Extended Liability-Threshold Model Klaus K. Holst Thomas Scheike, Jacob Hjelmborg 014-05-1 Heritability Twin studies Include both monozygotic (MZ) and dizygotic (DZ) twin
More informationMissing data. Patrick Breheny. April 23. Introduction Missing response data Missing covariate data
Missing data Patrick Breheny April 3 Patrick Breheny BST 71: Bayesian Modeling in Biostatistics 1/39 Our final topic for the semester is missing data Missing data is very common in practice, and can occur
More informationSCHOOL OF MATHEMATICS AND STATISTICS
Data provided: Tables of distributions MAS603 SCHOOL OF MATHEMATICS AND STATISTICS Further Clinical Trials Spring Semester 014 015 hours Candidates may bring to the examination a calculator which conforms
More informationData Analysis Using Regression and Multilevel/Hierarchical Models
Data Analysis Using Regression and Multilevel/Hierarchical Models ANDREW GELMAN Columbia University JENNIFER HILL Columbia University CAMBRIDGE UNIVERSITY PRESS Contents List of examples V a 9 e xv " Preface
More informationShould a Normal Imputation Model Be Modified to Impute Skewed Variables?
Sociological Methods and Research, 2013, 42(1), 105-138 Should a Normal Imputation Model Be Modified to Impute Skewed Variables? Paul T. von Hippel Abstract (169 words) Researchers often impute continuous
More informationMultilevel analysis quantifies variation in the experimental effect while optimizing power and preventing false positives
DOI 10.1186/s12868-015-0228-5 BMC Neuroscience RESEARCH ARTICLE Open Access Multilevel analysis quantifies variation in the experimental effect while optimizing power and preventing false positives Emmeke
More informationLAB ASSIGNMENT 4 INFERENCES FOR NUMERICAL DATA. Comparison of Cancer Survival*
LAB ASSIGNMENT 4 1 INFERENCES FOR NUMERICAL DATA In this lab assignment, you will analyze the data from a study to compare survival times of patients of both genders with different primary cancers. First,
More informationThe Effects of Autocorrelated Noise and Biased HRF in fmri Analysis Error Rates
The Effects of Autocorrelated Noise and Biased HRF in fmri Analysis Error Rates Ariana Anderson University of California, Los Angeles Departments of Psychiatry and Behavioral Sciences David Geffen School
More informationStatistical Models for Censored Point Processes with Cure Rates
Statistical Models for Censored Point Processes with Cure Rates Jennifer Rogers MSD Seminar 2 November 2011 Outline Background and MESS Epilepsy MESS Exploratory Analysis Summary Statistics and Kaplan-Meier
More informationT-Statistic-based Up&Down Design for Dose-Finding Competes Favorably with Bayesian 4-parameter Logistic Design
T-Statistic-based Up&Down Design for Dose-Finding Competes Favorably with Bayesian 4-parameter Logistic Design James A. Bolognese, Cytel Nitin Patel, Cytel Yevgen Tymofyeyef, Merck Inna Perevozskaya, Wyeth
More informationMEA DISCUSSION PAPERS
Inference Problems under a Special Form of Heteroskedasticity Helmut Farbmacher, Heinrich Kögel 03-2015 MEA DISCUSSION PAPERS mea Amalienstr. 33_D-80799 Munich_Phone+49 89 38602-355_Fax +49 89 38602-390_www.mea.mpisoc.mpg.de
More informationLecture Outline. Biost 517 Applied Biostatistics I. Purpose of Descriptive Statistics. Purpose of Descriptive Statistics
Biost 517 Applied Biostatistics I Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington Lecture 3: Overview of Descriptive Statistics October 3, 2005 Lecture Outline Purpose
More informationA FRAMEWORK FOR SIMULATIONS IN CLINICAL RESEARCH
A FRAMEWORK FOR SIMULATIONS IN CLINICAL RESEARCH with applications in small populations and rare diseases Tim Friede 1, Norbert Benda 2 1 University Medical Center Göttingen, Göttingen, Germany 2 Federal
More informationCity, University of London Institutional Repository
City Research Online City, University of London Institutional Repository Citation: Burmeister, E. and Aitken, L. M. (2012). Sample size: How many is enough?. Australian Critical Care, 25(4), pp. 271-274.
More informationOn Regression Analysis Using Bivariate Extreme Ranked Set Sampling
On Regression Analysis Using Bivariate Extreme Ranked Set Sampling Atsu S. S. Dorvlo atsu@squ.edu.om Walid Abu-Dayyeh walidan@squ.edu.om Obaid Alsaidy obaidalsaidy@gmail.com Abstract- Many forms of ranked
More informationDecision Making in Confirmatory Multipopulation Tailoring Trials
Biopharmaceutical Applied Statistics Symposium (BASS) XX 6-Nov-2013, Orlando, FL Decision Making in Confirmatory Multipopulation Tailoring Trials Brian A. Millen, Ph.D. Acknowledgments Alex Dmitrienko
More informationUnit 1 Exploring and Understanding Data
Unit 1 Exploring and Understanding Data Area Principle Bar Chart Boxplot Conditional Distribution Dotplot Empirical Rule Five Number Summary Frequency Distribution Frequency Polygon Histogram Interquartile
More informationEstimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel
Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel Jane Lange March 22, 2017 1 Acknowledgements Many thanks to the multiple project
More informationAnalyzing diastolic and systolic blood pressure individually or jointly?
Analyzing diastolic and systolic blood pressure individually or jointly? Chenglin Ye a, Gary Foster a, Lisa Dolovich b, Lehana Thabane a,c a. Department of Clinical Epidemiology and Biostatistics, McMaster
More informationChallenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
Annals of Oncology 27: 214 224, 2016 doi:10.1093/annonc/mdv550 Published online 16 November 2015 Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies S. Postel-Vinay 1,2,3
More informationComparison of methods for imputing limited-range variables: a simulation study
Rodwell et al. BMC Medical Research Methodology 2014, 14:57 RESEARCH ARTICLE Open Access Comparison of methods for imputing limited-range variables: a simulation study Laura Rodwell 1,2*, Katherine J Lee
More informationSensory Cue Integration
Sensory Cue Integration Summary by Byoung-Hee Kim Computer Science and Engineering (CSE) http://bi.snu.ac.kr/ Presentation Guideline Quiz on the gist of the chapter (5 min) Presenters: prepare one main
More informationGeorge B. Ploubidis. The role of sensitivity analysis in the estimation of causal pathways from observational data. Improving health worldwide
George B. Ploubidis The role of sensitivity analysis in the estimation of causal pathways from observational data Improving health worldwide www.lshtm.ac.uk Outline Sensitivity analysis Causal Mediation
More informationBiostatistics II
Biostatistics II 514-5509 Course Description: Modern multivariable statistical analysis based on the concept of generalized linear models. Includes linear, logistic, and Poisson regression, survival analysis,
More informationEstimation of delay to diagnosis and incidence in HIV using indirect evidence of infection dates
Stirrup and Dunn BMC Medical Research Methodology (2018) 18:65 https://doi.org/10.1186/s12874-018-0522-x RESEARCH ARTICLE Open Access Estimation of delay to diagnosis and incidence in HIV using indirect
More informationDiscussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK
Discussion Meeting for MCP-Mod Qualification Opinion Request Novartis 10 July 2013 EMA, London, UK Attendees Face to face: Dr. Frank Bretz Global Statistical Methodology Head, Novartis Dr. Björn Bornkamp
More informationAnalysis of Hearing Loss Data using Correlated Data Analysis Techniques
Analysis of Hearing Loss Data using Correlated Data Analysis Techniques Ruth Penman and Gillian Heller, Department of Statistics, Macquarie University, Sydney, Australia. Correspondence: Ruth Penman, Department
More informationA modified Hierarchical Continuous Reassessment Method (CRM) applied to a first-in-man study.
A modified Hierarchical Continuous Reassessment Method (CRM) applied to a first-in-man study. BAYES2010 20 May 2010 Anne Benoit Tom Jacobs Dominic, age 8, living with epilepsy Outline 2! First in Human
More informationPHASE 1 CLINICAL TRIALS: DESIGNS AND CONSIDERATIONS. Sarit Assouline, MD, MSc, FRCPC Associate professor, McGill University Jewish General Hospital
PHASE 1 CLINICAL TRIALS: DESIGNS AND CONSIDERATIONS Sarit Assouline, MD, MSc, FRCPC Associate professor, McGill University Jewish General Hospital Outline Introduction Goal of Phase I studies in oncology
More informationBayesian Nonparametric Methods for Precision Medicine
Bayesian Nonparametric Methods for Precision Medicine Brian Reich, NC State Collaborators: Qian Guan (NCSU), Eric Laber (NCSU) and Dipankar Bandyopadhyay (VCU) University of Illinois at Urbana-Champaign
More informationCan Family Strengths Reduce Risk of Substance Abuse among Youth with SED?
Can Family Strengths Reduce Risk of Substance Abuse among Youth with SED? Michael D. Pullmann Portland State University Ana María Brannan Vanderbilt University Robert Stephens ORC Macro, Inc. Relationship
More informationSample size calculation for a stepped wedge trial
Baio et al. Trials (2015) 16:354 DOI 10.1186/s13063-015-0840-9 TRIALS RESEARCH Sample size calculation for a stepped wedge trial Open Access Gianluca Baio 1*,AndrewCopas 2, Gareth Ambler 1, James Hargreaves
More informationMeta-analysis of few small studies in small populations and rare diseases
Meta-analysis of few small studies in small populations and rare diseases Christian Röver 1, Beat Neuenschwander 2, Simon Wandel 2, Tim Friede 1 1 Department of Medical Statistics, University Medical Center
More informationEmpirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study
Empirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study Jonathan Sterne, University of Bristol, UK Acknowledgements: Tony Ades, Bodil Als-Nielsen,
More informationC-reactive protein levels in relation to various features of non-alcoholic fatty liver
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients Esther Zimmermann 1,2, Rodolphe Anty 3,4,5, Joan Tordjman 6,7,8, An Verrijken 9, Philippe
More informationSaunders, O 1, Asseburg, C 2, O Reilly, K 3, Sly, I 1, Lee, D 1
Modelling Alzheimer s disease progression using a multivariate model for the associated outcomes of cognition, behaviour and functioning: Data from the ICTUS Study Saunders, O 1, Asseburg, C, O Reilly,
More informationRANDOMIZATION. Outline of Talk
RANDOMIZATION Basic Ideas and Insights Marvin Zelen Harvard University Graybill Conference Ft.Collins, Colorado June 11, 2008 Outline of Talk Introduction Randomized vs. Observational Studies Conditioning
More informationPasteur course MODELING OF INFECTIOUS DISEASES
Pasteur course MODELING OF INFECTIOUS DISEASES PROGRAM 2017-2018 Modeling of Infectious Diseases 2017-2018 CO-DIRECTORS OF THE COURSE Pierre -Yves BOËLLE Université Pierre et Marie Curie Hôpital Saint
More informationLecture 5: Sequential Multiple Assignment Randomized Trials (SMARTs) for DTR. Donglin Zeng, Department of Biostatistics, University of North Carolina
Lecture 5: Sequential Multiple Assignment Randomized Trials (SMARTs) for DTR Introduction Introduction Consider simple DTRs: D = (D 1,..., D K ) D k (H k ) = 1 or 1 (A k = { 1, 1}). That is, a fixed treatment
More informationUnderstandable Statistics
Understandable Statistics correlated to the Advanced Placement Program Course Description for Statistics Prepared for Alabama CC2 6/2003 2003 Understandable Statistics 2003 correlated to the Advanced Placement
More informationStatistical Tests of Agreement Based on Non-Standard Data
Statistical Tests of Agreement Based on Non-Standard Data Elizabeth Stanwyck Bimal Sinha Department of Mathematics and Statistics University of Maryland, Baltimore County Barry Nussbaum Office of Environmental
More informationApplied Medical. Statistics Using SAS. Geoff Der. Brian S. Everitt. CRC Press. Taylor Si Francis Croup. Taylor & Francis Croup, an informa business
Applied Medical Statistics Using SAS Geoff Der Brian S. Everitt CRC Press Taylor Si Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Croup, an informa business A
More informationClinical trial design issues and options for the study of rare diseases
Clinical trial design issues and options for the study of rare diseases November 19, 2018 Jeffrey Krischer, PhD Rare Diseases Clinical Research Network Rare Diseases Clinical Research Network (RDCRN) is
More informationDynamic prediction using joint models for recurrent and terminal events: Evolution after a breast cancer
Dynamic prediction using joint models for recurrent and terminal events: Evolution after a breast cancer A. Mauguen, B. Rachet, S. Mathoulin-Pélissier, S. Siesling, G. MacGrogan, A. Laurent, V. Rondeau
More informationHow could we design studies on PRO data? The PLANIPRO project
How could we design studies on PRO data? The PLANIPRO project Véronique Sébille, Myriam Blanchin, Alice Guilleux, Alexandra Rouquette, Sarah Amri, Mohand-Larbi Feddag, Tanguy Le Néel, Gildas Kubis, Bruno
More informationDesigns for Partially-Ordered Phase I Trials : Combinations of Agents and Groups of Patients. Mark Conaway University of Virginia
Designs for Partially-Ordered Phase I Trials : Combinations of Agents and Groups of Patients Mark Conaway University of Virginia 1 Novel designs for new types of studies LoRusso, Boerner and Seymour (2010)
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationRasch modelling to deal with changes in the questionnaires used during long-term follow-up of cohort studies: a simulation study
Rouquette et al. BMC Medical Research Methodology (2016) 16:105 DOI 10.1186/s12874-016-0211-6 RESEARCH ARTICLE Open Access Rasch modelling to deal with changes in the questionnaires used during long-term
More informationCancer Incidence Predictions (Finnish Experience)
Cancer Incidence Predictions (Finnish Experience) Tadeusz Dyba Joint Research Center EPAAC Workshop, January 22-23 2014, Ispra Rational for making cancer incidence predictions Administrative: to plan the
More informationProfile Analysis. Intro and Assumptions Psy 524 Andrew Ainsworth
Profile Analysis Intro and Assumptions Psy 524 Andrew Ainsworth Profile Analysis Profile analysis is the repeated measures extension of MANOVA where a set of DVs are commensurate (on the same scale). Profile
More informationSelection of Linking Items
Selection of Linking Items Subset of items that maximally reflect the scale information function Denote the scale information as Linear programming solver (in R, lp_solve 5.5) min(y) Subject to θ, θs,
More informationJonathan D. Sugimoto, PhD Lecture Website:
Jonathan D. Sugimoto, PhD jons@fredhutch.org Lecture Website: http://www.cidid.org/transtat/ 1 Introduction to TranStat Lecture 6: Outline Case study: Pandemic influenza A(H1N1) 2009 outbreak in Western
More informationTreatment effect estimates adjusted for small-study effects via a limit meta-analysis
Treatment effect estimates adjusted for small-study effects via a limit meta-analysis Gerta Rücker 1, James Carpenter 12, Guido Schwarzer 1 1 Institute of Medical Biometry and Medical Informatics, University
More informationST440/550: Applied Bayesian Statistics. (10) Frequentist Properties of Bayesian Methods
(10) Frequentist Properties of Bayesian Methods Calibrated Bayes So far we have discussed Bayesian methods as being separate from the frequentist approach However, in many cases methods with frequentist
More informationReceived: 14 April 2016, Accepted: 28 October 2016 Published online 1 December 2016 in Wiley Online Library
Research Article Received: 14 April 2016, Accepted: 28 October 2016 Published online 1 December 2016 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.7171 One-stage individual participant
More informationMeta-analysis of two studies in the presence of heterogeneity with applications in rare diseases
Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases Christian Röver 1, Tim Friede 1, Simon Wandel 2 and Beat Neuenschwander 2 1 Department of Medical Statistics,
More informationEstimation of effect sizes in the presence of publication bias: a comparison of meta-analysis methods
Estimation of effect sizes in the presence of publication bias: a comparison of meta-analysis methods Hilde Augusteijn M.A.L.M. van Assen R. C. M. van Aert APS May 29, 2016 Today s presentation Estimation
More informationTHE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER GRADUATE COLLEGE A COMPARISON OF STATISTICAL ANALYSIS MODELING APPROACHES FOR STEPPED-
THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER GRADUATE COLLEGE A COMPARISON OF STATISTICAL ANALYSIS MODELING APPROACHES FOR STEPPED- WEDGE CLUSTER RANDOMIZED TRIALS THAT INCLUDE MULTILEVEL CLUSTERING,
More informationThe questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs
The questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs Elizabeth Garrett-Mayer, PhD Associate Professor Director of Biostatistics, Hollings Cancer
More information